Moderna (MRNA) said Friday it has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency for mRESVIA, its respiratory syncytial virus vaccine for adults 60 and over.
RSV is a highly contagious seasonal virus that causes lower respiratory tract infections and pneumonia, the company said.
The approval is based on the phase 3 ConquerRSV trial, which included around 37,000 adults aged 60 and older across 22 countries, the company said, adding that the trial found no serious safety concerns.
MRNA shares were 0.6% higher in recent trading.
Price: 31.28, Change: +0.19, Percent Change: +0.61
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。